Blockading immunecheckpoints such as the PD-1/PD-L1 complex demonstrated remarkable clinical benefits with a long immunogenic response in the tumor microenvironment, thus leading to a paradigm shift in cancer therapies. Here, CD274 is linked to neoplasm.